Home | Members | Contact Us

 

 

Protocol and Consent Forms

Last Updated:  July 30, 2010

 

  Press Alt-S after clicking "Find in Page" to continue searching the page.

NOTE:  Limited funding may be available to offset costs on certain protocols.  Contact KCCOP for more information.

Brain/CNS

Also, see Cancer Control section for symptom management/prevention trials.

Glioma

CTSU N0577:  Protocol Summary | Consent Form  

ANAPLASTIC GLIOMA (oligodendroglioma, mixed, or astrocytoma), post-surgical dx, Co-deleted 1p/19q, Central Path Review required pre-regist; RT vs Temozolomide vs RT + concurrent & adjuv Temozolomide (see Neurocognitive Certification & IMRT requirements in protocol)

RTOG 0837:  Protocol Summary | Consent Form     

GLIOMA, Glioblastoma or Gliosarcoma (WHO grade IV), newly dx; Central Path Review, Conventional chemoradiation + Adjuv Temozolimide + Cediranib/placebo (see RT credentialing requirements in protocol)

RTOG 0825:  Protocol Summary | Consent Form

GLIOMA, Glioblastoma or Gliosarcoma (Grade IV), newly dx; Central Path Review ! Conventional Concurrent Chemoradiation + Adjuv Temozolomide + Bevacizumab/placebo (double-blind) (See RT & Neurocognitive Function Testing requirements in protocol.)

RTOG 0627:  Protocol Summary | Consent Form     

GLIOMA, glioblastoma multiforme or gliosarcoma, recur, prior RT & Temozolomide required; Eval of Dasatinib

Meningioma

RTOG 0539:  Protocol Summary | Consent Form       

MENINGIOMA, WHO Grade I, II, or III, new dx or recur, any resection extent; Observation for low-risk & RT for intermed- or high-risk groups (see RT credentialing requirements in protocol)

 TOP

Breast

Also, see Cancer Control section for symptom management/prevention trials.

Stage 0

CTSU PACCT-1:  Protocol Summary | Consent Form

Adj., Stgs 0, I , Selected II, Hormone+, N0, Candidate for cytotoxic + hormonal therapy; Trial of Individualized Options for Tx (TAILORx Trial)

NSABP B-39:  Protocol Summary | Consent Form

Adj., Stg. 0, I, II; Conventional Whole Breast RT vs Partial Breast RT (Multi-Catheter, Mammosite, or 3D-CRT) (Sites need approval - check RT requirements in protocol.)

Stage I

CTSU PACCT-1:  Protocol Summary | Consent Form

Adj., Stgs 0, I , Selected II, Hormone+, N0, Candidate for cytotoxic + hormonal therapy; Trial of Individualized Options for Tx (TAILORx Trial)

IBCSG 25-02:  Protocol Summary | Consent Form 

Adj., T1-3, N0-2, M0, Pre-meno, ER+ &/or PgR+; Triptorelin + TMX x 5 yr vs Triptorelin + Exemestane x 5 yrs (both arms +/- adjuv chemo) (PARTICIPATION LIMITED BY STUDY GROUP TO PRIOR ACCRUING SITES:  SLCI & St. Joseph Oncology)

NSABP B-44-I:  Protocol Summary | Pre-Randomization (HER2) Consent | Treatment Consent Form

Adj., Stgs I-III, HER2(+), Node(+) or High Risk Node(-); Taxol + Carboplatin + Trastuzumab ! Trastuzumab +/- Bevacizumab (INDUSTRY TRIAL - WILL RECEIVE FUNDS, NOT CREDITS.  PARTICIPATION LIMITED - ONLY SLH-KC CURRENTLY APPROVED.)

NSABP B-46-I:  Protocol Summary | Consent Form

Adj., Stgs I-IIIC (no IIIB), Node(+) or High-risk Node(-), HER2(-); Docetaxel + Doxorubicin + Cyclophosphamide vs Docetaxel + Cyclophosphamide vs Docetaxel + Cyclophosphamide + Bevacizumab (Industry trial – will receive funds, not credits.  participation limited.)

CALGB 40101: Protocol Summary | Consent Form 

Adj., T1‑4, N0-3, M0; Cyclophosphamide + Doxorubicin vs Paclitaxel

SWOG S0221:  Protocol Summary | Consent Form

Adj., Stg I, II, III, Node+ or Hi-Risk Node -, male pts allowed; Continuous Schedule Doxorubicin+Cyclophosphade+GCSF vs q2wk Doxorubicin+Cyclophosphade, both ! Taxol (q2wks vs weekly x 12 wks)

NSABP B-39:  Protocol Summary | Consent Form

Adj., Stg. 0, I, II; Conventional Whole Breast RT vs Partial Breast RT (Multi-Catheter, Mammosite, or 3D-CRT) (Sites need approval - check RT requirements in protocol.)

CTSU N063D (ALTTO):  Protocol Summary | Consent Form
(Neo-)Adj., known ER/PgR or ER, HER2+, must have plans for concurrent non-anthracycline platinum chemo; Eval of sequences of Lapatinib &/or Trastuzumab (only Design 2B still open)

Stage II

CTSU PACCT-1:  Protocol Summary | Consent Form

Adj., Stgs 0, I , Selected II, Hormone+, N0, Candidate for cytotoxic + hormonal therapy; Trial of Individualized Options for Tx (TAILORx Trial)

IBCSG 25-02:  Protocol Summary | Consent Form 

Adj., T1-3, N0-2, M0, Pre-meno, ER+ &/or PgR+; Triptorelin + TMX x 5 yr vs Triptorelin + Exemestane x 5 yrs (both arms +/- adjuv chemo) (PARTICIPATION LIMITED BY STUDY GROUP TO PRIOR ACCRUING SITES:  SLCI & St. Joseph Oncology)

NSABP B-44-I:  Protocol Summary | Pre-Randomization (HER2) Consent | Treatment Consent Form

Adj., Stgs I-III, HER2(+), Node(+) or High Risk Node(-); Taxol + Carboplatin + Trastuzumab ! Trastuzumab +/- Bevacizumab (INDUSTRY TRIAL - WILL RECEIVE FUNDS, NOT CREDITS.  PARTICIPATION LIMITED - ONLY SLH-KC CURRENTLY APPROVED.)

NSABP B-46-I:  Protocol Summary | Consent Form

Adj., Stgs I-IIIC (no IIIB), Node(+) or High-risk Node(-), HER2(-); Docetaxel + Doxorubicin + Cyclophosphamide vs Docetaxel + Cyclophosphamide vs Docetaxel + Cyclophosphamide + Bevacizumab (Industry trial – will receive funds, not credits.  participation limited.)

ACOSOG Z1071:  Protocol Summary | Consent Form

Surg, T0-4, N1-2, M0; Eval of SLN & ALND following neo-adjuv therapy

CALGB 40603:  Protocol Summary | Consent Form

Neoadj., Stg II-IIIA, Hormone-Receptor Poor/HER2-, resectable; Carboplatin +/- Bevacizumab + weekly Paclitaxel ! Dose-Dense AC

CTSU N063D (ALTTO):  Protocol Summary | Consent Form
(Neo-)Adj., known ER/PgR or ER, HER2+, must have plans for concurrent non-anthracycline platinum chemo; Eval of sequences of Lapatinib &/or Trastuzumab (only Design 2B still open)

ACOSOG Z1031:  Protocol Summary | Consent Form | Supplemental Sample Consent | Optional Genome Research Consent

Neoadj., T2-4c, any N, M0, Post-meno, ER+; 16-18 wks Exemestane vs Letrozole vs Anastrozole!Bx ! Continued AI therapy, chemo, or surg (depending on Ki67 score)
NSABP B-41:  Protocol Summary | Consent Form  

Neoadj., Stgs IIA-B & selected Stg IIIA, HER2+, palpable & operable; AC ! Taxol + Trastuzumab vs AC ! Taxol + Lapatinib vs AC ! Taxol + Trastuzumab + Lapatinib (all Arms followed by Surg & post-surg Trastuzumab, & required correlative studies for path CR) (INDUSTRY TRIAL - WILL RECEIVE FUNDS, NOT CREDITS.  PARTICIPATION LIMITED - ONLY SLH-KC CURRENTLY APPROVED.)

SWOG S0221:  Protocol Summary | Consent Form

Adj., Stg I, II, III, Node+ or Hi-Risk Node -, male pts allowed; Continuous Schedule Doxorubicin+Cyclophosphade+GCSF vs q2wk Doxorubicin+Cyclophosphade, both ! Taxol (q2wks vs weekly x 12 wks)

NSABP B-39:  Protocol Summary | Consent Form

Adj., Stg. 0, I, II; Conventional Whole Breast RT vs Partial Breast RT (Multi-Catheter, Mammosite, or 3D-CRT) (Sites need approval - check RT requirements in protocol.)

CALGB 40101: Protocol Summary | Consent Form 

Adj., T1‑4, N0-3, M0; Cyclophosphamide + Doxorubicin vs Paclitaxel

Stage III

CALGB 40101:  Protocol Summary | Consent Form

Adj., T1‑4, N0-3, M0; Cyclophosphamide + Doxorubicin vs Paclitaxel

NSABP B-44-I:  Protocol Summary | Pre-Randomization (HER2) Consent | Treatment Consent Form

Adj., Stgs I-III, HER2(+), Node(+) or High Risk Node(-); Taxol + Carboplatin + Trastuzumab ! Trastuzumab +/- Bevacizumab (INDUSTRY TRIAL - WILL RECEIVE FUNDS, NOT CREDITS.  PARTICIPATION LIMITED - ONLY SLH-KC CURRENTLY APPROVED.)

CALGB 40502:  Protocol Summary | Consent Form

Stg IIIC or IV, known HER-2/neu, ER, & PgR status; 1st-line randomized trial of Paclitaxel vs Nanoparticle Albumin-Bound Paclitaxel + Bevacizumab vs Ixabepilone + Bevacixumab (all given weekly)

NSABP B-46-I:  Protocol Summary | Consent Form

Adj., Stgs I-IIIC (no IIIB), Node(+) or High-risk Node(-), HER2(-); Docetaxel + Doxorubicin + Cyclophosphamide vs Docetaxel + Cyclophosphamide vs Docetaxel + Cyclophosphamide + Bevacizumab (Industry trial – will receive funds, not credits.  participation limited.)

ACOSOG Z1071:  Protocol Summary | Consent Form

Surg, T0-4, N1-2, M0; Eval of SLN & ALND following neo-adjuv therapy

SWOG S0221:  Protocol Summary | Consent Form

Adj., Stg I, II, III, Node+ or Hi-Risk Node -, male pts allowed; Continuous Schedule Doxorubicin+Cyclophosphade+GCSF vs q2wk Doxorubicin+Cyclophosphade, both ! Taxol (q2wks vs weekly x 12 wks)

CALGB 40603:  Protocol Summary | Consent Form

Neoadj., Stg II-IIIA, Hormone-Receptor Poor/HER2-, resectable; Carboplatin +/- Bevacizumab + weekly Paclitaxel ! Dose-Dense AC

CTSU N063D (ALTTO):  Protocol Summary | Consent Form

(Neo-)Adj., known ER/PgR or ER, HER2+, must have plans for concurrent non-anthracycline platinum chemo; Eval of sequences of Lapatinib &/or Trastuzumab (only Design 2B still open)

ACOSOG Z1031:  Protocol Summary | Consent Form | Supplemental Sample Consent | Optional Genome Research Consent

Neoadj., T2-4c, any N, M0, Post-meno, ER+; 16-18 wks Exemestane vs Letrozole vs Anastrozole!Bx ! Continued AI therapy, chemo, or surg (depending on Ki67 score)
NSABP B-41:  Protocol Summary | Consent Form  

Neoadj., Stgs IIA-B & selected Stg IIIA, HER2+, palpable & operable; AC ! Taxol + Trastuzumab vs AC ! Taxol + Lapatinib vs AC ! Taxol + Trastuzumab + Lapatinib (all Arms followed by Surg & post-surg Trastuzumab, & required correlative studies for path CR) (INDUSTRY TRIAL - WILL RECEIVE FUNDS, NOT CREDITS.  PARTICIPATION LIMITED - ONLY SLH-KC CURRENTLY APPROVED.)

Metastatic / Recurrent

CALGB 40502:  Protocol Summary | Consent Form

Stg IIIC or IV, known HER-2/neu, ER, & PgR status; 1st-line randomized trial of Paclitaxel vs Nanoparticle Albumin-Bound Paclitaxel + Bevacizumab vs Ixabepilone + Bevacixumab (all given weekly)

 TOP

Cancer Control

Cancer Control:  Any Site

SWOG S0702:  Protocol Summary | Consent Form

Bone Mets from any site, plan to receive Zoledronic acid; Observational study of ONJ

MDA 2007-0791:  Protocol Summary | Consent Form

Any site, self-reported pain (any cause), prescribed or using Morphine or Oxycodone SR; Oral Methadone vs switching between Morphine SR & Oxycodone SR (see protocol for Methadone prescriber training requirement)

URCC U1105:  Protocol Summary | Consent Form  

Any cancer dx, no prior chemo, planned Cisplatin, Carboplatin, Oxaliplatin, Doxorubicin, or Epirubicin-containing regimen w/o concurrent RT or IFN; 4 Double-blind regimens for preventing delayed nausea

URCC 08106:  Protocol Summary | Consent Form  

Any cancer dx (no leukemia), M0, chemo naive, planning to start chemo lasting >6 wks (tx cycles can be 2, 3, or 4 wks); Effects of exercise on cancer-related fatigue (staff administering exercise intervention must be trained & approved by URCC)

Cancer Control:  Breast

NSABP B-43-CC:  Protocol Summary | Pre-Entry HER2 Test Consent Form | Consent Form    

Adj., Stg 0 (DCIS or mixed DCIS/LCIS), post-lumpectomy, HER2+; RT +/- concurrent Trastuzumab

CALGB 70501:  Protocol Summary | Consent Form

Companion Study to CALGB 30607, 40502, 70604, 80405, + others to be opened in future; Symptom & Perf Status self-reporting via Internet (dedicated CRA for this study must be available; laptop will be provided; CRA must complete training by KCCOP)

RTOG 0517:  Protocol Summary | Consent Form

BONE METS (from Breast, Lung, Prostate), must complete EBRT <14 days pre-regist, chemo or hormonal therapy allowed; Zometa+Vit D+Ca +/- Single Dose Sr-89 or Sm-153

CALGB 70301:  Protocol Summary | Consent Form

Companion Study to CALGB 40101; QOL, Employment & Informal Care Cost Analysis

CALGB 70604:  Protocol Summary | Consent Form

BONE METS (from Breast, Prostate, Mult Myeloma), no prior IV bisphosphonates or radiopharmaceuticals; Standard vs Longer Dosing Interval of Zoledronic Acid

Cancer Control:  GI

NSABP P-5:  Protocol Summary | Consent Form

COLON, resected adenocarcinoma, Stg I or II, post-adjuv therapy; Rosuvastatin vs placebo polyp prevention trial

CALGB 70501:  Protocol Summary | Consent Form

Companion Study to CALGB 30607, 40502, 70604, 80405, + others to be opened in future; Symptom & Perf Status self-reporting via Internet (dedicated CRA for this study must be available; laptop will be provided; CRA must complete training by KCCOP)

MDA 2008-0005:  Protocol Summary | Consent Form

COLORECTAL, Mets, scheduled to receive Irinotecan alone or w/5-FU, Cetuximab, or other biologics; CASAD vs placebo for diarrhea tx/prevention  (PARTICIPATION CURRENTLY LIMITED TO SLCI & RMC)

Cancer Control:  GU

RTOG 0517:  Protocol Summary | Consent Form

BONE METS (from Breast, Lung, Prostate), must complete EBRT <14 days pre-regist, chemo or hormonal therapy allowed; Zometa+Vit D+Ca +/- Single Dose Sr-89 or Sm-153

CALGB 70604:  Protocol Summary | Consent Form

BONE METS (from Breast, Prostate, Mult Myeloma), no prior IV bisphosphonates or radiopharmaceuticals; Standard vs Longer Dosing Interval of Zoledronic Acid

Cancer Control:  Gyn

GOG-0237:  Protocol Summary | Consent Form

CERVICAL, Atypical glandular cells; Analysis of CA-IX, p16, proliferative markers, & HPV in diagnosing cervical lesions

GOG-0259:  Protocol Summary | Consent Form

OVARIAN, FALLOPIAN TUBE, or PRIM PERITONEAL, Recur or Persis, active disease or tx not required; Nurse-Delivered WRITE Symptoms vs Self-Directed WRITE Symptoms vs Care as Usual

Cancer Control:  Lung

RTOG 0517:  Protocol Summary | Consent Form

BONE METS (from Breast, Lung, Prostate), must complete EBRT <14 days pre-regist, chemo or hormonal therapy allowed; Zometa+Vit D+Ca +/- Single Dose Sr-89 or Sm-153

CALGB 70501:  Protocol Summary | Consent Form

Companion Study to CALGB 30607, 40502, 70604, 80405, + others to be opened in future; Symptom & Perf Status self-reporting via Internet (dedicated CRA for this study must be available; laptop will be provided; CRA must complete training by KCCOP)

SWOG S0424:  Protocol Summary | Consent Form  

Molecular Epidemiology Study; NSCLC in Smoking & Non-Smoking Men/Women

Cancer Control:  Lymphoma

SWOG 8819:  Protocol Summary  (no consent form)

Path Companion to SWOG-coordinated protocols for prev untreated, NH lymphoma

Cancer Control:  Myeloma

CALGB 70604:  Protocol Summary | Consent Form

BONE METS (from Breast, Prostate, Mult Myeloma), no prior IV bisphosphonates or radiopharmaceuticals; Standard vs Longer Dosing Interval of Zoledronic Acid

 TOP

GI

Also, see Cancer Control section for symptom management/prevention trials.

Colon

CALGB 80702:  Protocol Summary | Consent Form

COLON, Stg III, resected; 6 vs 12 txs of adjuv FOLFOX + Celecoxib/placebo

Colorectal

CALGB 80405:  Protocol Summary | Consent Form

COLORECTAL, Adenocarcinoma (Adv or Mets), Untreated, Wild type K-ras (determined pre-regist ); Either FOLFOX or FOLFIRI with either Bevacizumab or Cetuximab

Gallbladder

SWOG S0941:  Protocol Summary | Consent Form

GALLBLADDER or CHOLANGIOCARCINOMA, locally adv (unresectable) or mets; Sorafenib + Erlotinib

Liver

CALGB 80802:  Protocol Summary | Consent Form

HEPATOCELLULAR, locally adv or mets, no prior allografts; Doxorubicin +/- Sorafenib

CTSU E1208:  Protocol Summary | Consent Form                

HEPATOCELLULAR (limited to liver), unresectable; Chemoemobilization +/- Sorafenib

Pancreas

SWOG S0727 :  Protocol Summary | Consent Form            

PANCREAS, Stg IV, Unresec, adenocarcinoma; Gemcitabine + Erlotinib +/- IMC-A12 as 1st line tx

Rectal

NSABP R-04:  Protocol Summary | Consent Form

RECTAL, Stgs II-III, operable invasive adenocarcinoma; Pre-op RT + Capecitabine +/- Oxal vs Pre-op RT + CI 5-FU +/- Oxal

Other

SWOG S0941:  Protocol Summary | Consent Form

GALLBLADDER or CHOLANGIOCARCINOMA, locally adv (unresectable) or mets; Sorafenib + Erlotinib

 TOP

GU

Also, see Cancer Control section for symptom management/prevention trials.

Prostate:  Stage II

RTOG 0534:  Protocol Summary | Consent Form

PROSTATE, Adenocarcinoma, T3N0/Nx or T2N0/Nx +/- positive surg margin, rising PSA post-radical prostatectomy; Prostate Bed RT (PBRT) vs PBRT + Neoadjuv & Concurrent short-term androgen depriv (NC-STAD) vs PBRT + NC-STAD + Pelvic Lymph Node RT (see RT & neurocognitive function credentialing requirements in protocol)

RTOG 0232:  Protocol Summary | Consent Form

PROSTATE, T1c-2b, Nx/N0, M0; Ext Beam RT+Transperineal Interstitial Permanent Brachytherapy vs Brachytherapy alone (Sites need approval - check RT requirements in protocol.)

RTOG 0815:  Protocol Summary | Consent Form

PROSTATE, Adenocarcinoma, Interm risk (Gleason 7, PSA>10 & <20, &/or Clin Stg T2b-T2c); Dose-Escal RT +/- Short-Term Androgen Deprivation (see RT credentialing requirements in protocol)

Prostate:  Stage III

RTOG 0534:  Protocol Summary | Consent Form

PROSTATE, Adenocarcinoma, T3N0/Nx or T2N0/Nx +/- positive surg margin, rising PSA post-radical prostatectomy; Prostate Bed RT (PBRT) vs PBRT + Neoadjuv & Concurrent short-term androgen depriv (NC-STAD) vs PBRT + NC-STAD + Pelvic Lymph Node RT (see RT & neurocognitive function credentialing requirements in protocol)

Prostate:  Stage IV

MDA ID-00156 :  Protocol Summary | Consent Form 

PROSTATE, Adenocarcinoma, Stg IV, Androgen-Indep; Induction Chemo ! Doxorubicin +/- single dose

Strontium-89

Renal

CTSU E2804:  Protocol Summary | Consent Form  

RENAL, clear cell w/<25% any other histology, mets untreatable by RT or surg, prior nephrectomy (some exceptions); VEGF, RAF Kinase, & MTOR Comb. Targeted Therapy w/Bevacizumab, Sorafenib, & Temsirolimus

CTSU E2805:  Protocol Summary | Consent Form  

RENAL, Resectable, no distant mets; Double-blind adjuv Sunitinib vs Sorafenib vs placebo

Urinary Tract

CALGB 90601:  Protocol Summary | Consent Form

URINARY TRACT (Renal Pelvis, Ureter, Bladder, Prostate, or Urethra), Transitional cell, Mets or Locally Adv; Gemcitabine + Cisplatin + Bevacizumab/placebo

 TOP

GYN

Also, see Cancer Control section for symptom management/prevention trials.

Endometrial

GOG-0248:  Protocol Summary | Consent Form 

ENDOMETRIAL, Stg III-IV, persis, or recur, likely incurable by surg or RT; Eval of Temsirolimus

RTOG 0921:  Protocol Summary | Consent Form 

ENDOMETRIAL, post-hysterectomy for uterine ca & post-BSO, Stgs IC, IIA-B, III, & IVA; IMRT + concurrent Cisplatin & Bevacizumab à Carboplatin + Paclitaxel (see RT credentialing requirements in protocol)

GOG-0249:  Protocol Summary | Consent Form 

ENDOMETRIAL, Post-Hyst/BSO & peritoneal cytol, Stg I-IIA (high-interm risk), IIB (occult, any histol, +/- risk factors), I-IIB (occult, serous or clear, +/- risk factors); Pelvic RT vs Vaginal Cuff Brachy + Paclitaxel & Carboplatin

Ovarian

GOG-0126T:  Protocol Summary | Consent Form

OVARIAN or FALLOPIAN TUBE (Recur or Persis) or PERITONEAL (Prim), platinum-resistant or -refractory; Belinostat + Carboplatin

GOG 0212:  Protocol Summary | Consent Form

OVARIAN or FALLOPIAN TUBE (Adv, Epith) or PERITONEAL (Prim), CR after Prim Platinum/Taxane chemo; Maint Chemo (12 monthly cycles of Paclitaxel or CT-2103) vs No Tx until relapse (PARTICIPATION LIMITED)

 TOP

Leukemia

Also, see Cancer Control section for symptom management/prevention trials.

Acute

SWOG E1905:  Protocol Summary | Consent Form       

MDS, CMMoL (Dysplatic), or AML (Multilineage Dysplasia); Azacitidine +/- Etinostat

Chronic

CALGB 10404:  Protocol Summary | Consent Form       

CLL (B-cell), symptomatic & active intermediate or high-risk Rai staging, no prior tx; Randomized study of 4 Fludarabine/Antibody Combinations

SWOG E1905:  Protocol Summary | Consent Form       

MDS, CMMoL (Dysplatic), or AML (Multilineage Dysplasia); Azacitidine +/- Etinostat

CTSU E2905:  Protocol Summary | Consent Form   

MDS or non-proliferative CMML, Low- or Intermediate-1-risk, symptomatic anemia; Frequency of Major Erythroid Response to Lenalidomide +/- Epoetin Alfa

Ancillary

SWOG 9007:  Protocol Summary | Consent Form

MANDATORY Cytometry Companion to all Leukemia tx protocols

SWOG S9910:  Protocol Summary | Consent Form

Ancillary; specimen submission to Centralized Reference Lab & Tissue Repository

CALGB 8461:  Protocol Summary | Consent Form

Cytogenetics study for prev untreated AML, ALL, MDS

CALGB 9665:  Protocol Summary | Consent Form

Tissue Bank for prev untreated leukemia pts (acute or chronic) & MDS

CALGB 9760:  Protocol Summary | Consent Form

Multidrug Resistance studies for prev untreated AML & ALL

 TOP

Lung

Also, see Cancer Control section for symptom management/prevention trials.

NSC:  Stage I

CALGB 140503:  Protocol Summary | Consent Form

NSC, peripheral nodule <2cm, N0, M0; Lobectomy vs Sublobar Resection (if pt is randomized to Lobectomy arm & surgeon plans to use VATS procedure, surgeon must be credentialed per protocol)

RTOG 0915:  Protocol Summary | Consent Form

NSC, Stgs IA-IB, no bronchioalveolar cell, medically inoperable; Eval of 2 SBRT schedules (see RT credentialing requirements in protocol)

CTSU E1505:  Protocol Summary | Consent Form

NSC, Stgs IB (>4cm) - IIIA, completely resected; 1 of 4 chemo regimens +/- Bevacizumab

RTOG 0813:  Protocol Summary | Consent Form

NSC, Stg I, centrally located, medically inoperable; Eval of Stereotactic Lung RT (see RT credentialing requirements in protocol)

NSC:  Stage II

CTSU E1505:  Protocol Summary | Consent Form

NSC, Stgs IB (>4cm) - IIIA, completely resected; 1 of 4 chemo regimens +/- Bevacizumab

NSC:  Stage IIIA

CTSU E1505:  Protocol Summary | Consent Form

NSC, Stgs IB (>4cm) - IIIA, completely resected; 1 of 4 chemo regimens +/- Bevacizumab

CALGB 30605Protocol Summary | Consent Form

NSC, Stgs IIIA-B (Unresectable), no prior chemo or RT for NSC; Induction Chemo ! Thoracic RT + Erlotinib

RTOG 0617:  Protocol Summary | Consent Form        

NSC, Stgs IIIA-B (Unresectable), M0; Stand Dose (60Gy) vs High-Dose (74Gy) Conformal RT + Concurrent & Consolidation Carbo/Taxol +/- Cetuximab (Sites need approval – check RT requirements in protocol)

NSC:  Stage IIIB

CALGB 30605Protocol Summary | Consent Form

NSC, Stgs IIIA-B (Unresectable), no prior chemo or RT for NSC; Induction Chemo ! Thoracic RT + Erlotinib

CALGB 30607:  Protocol Summary | Consent Form  

NSC, Stg IIIB-IV, must have rcvd 4 cycles of platinum-based chemo +/- Bevacizumab & had no progression; Sunitinib vs placebo

RTOG 0617:  Protocol Summary | Consent Form        

NSC, Stgs IIIA-B (Unresectable), M0; Stand Dose (60Gy) vs High-Dose (74Gy) Conformal RT + Concurrent & Consolidation Carbo/Taxol +/- Cetuximab (Sites need approval – check RT requirements in protocol)

NSC:  Stage IV

CALGB 30607:  Protocol Summary | Consent Form  

NSC, Stg IIIB-IV, must have rcvd 4 cycles of platinum-based chemo +/- Bevacizumab & had no progression; Sunitinib vs placebo

SWOG S0819:  Protocol Summary | Consent Form

NSC, Stg IV, new dx or recur; Carboplatin/Paclitaxel vs Carboplatin/Paclitaxel/Bevacizumab +/- Concurrent Cetuximab

 TOP

Lymphoma

Also, see Cancer Control section for symptom management/prevention trials.

Non-Hodgkin's

CALGB 50401:   Protocol Summary | Consent Form 

NH, Not Rituximab-refractory, Grade 1, 2, or 3a, Follicular; Lenalidomide vs Rituximab + Lenalidomide

Ancillary

SWOG 8947:   Protocol Summary | Consent Form 

Serum Companion to SWOG-coord protocols for prev untreated, NH lymphoma

 TOP

Melanoma

Also, see Cancer Control section for symptom management/prevention trials.

CTSU E1697:  Protocol Summary | Consent Form                

Stg T2b N0, T3a-b N0, T4a-b N0, or T1-4 N1a-2a (micro), cutaneous, post-wide excision +/- lymphadenectomy; High-Dose IFN-α2b (x 4 wks)

SWOG S0826:  Protocol Summary | Consent Form              

Stg IV, cutaneous or mucosal origin, Eval of SCH 727965

Myeloma

Also, see Cancer Control section for symptom management/prevention trials.

SWOG S0777:  Protocol Summary | Consent Form

MM, no prior tx, no intent for immed Autologous Stem Cell Transplant; Lenalidomide + Low Dose Dexamethasone +/- Bortezomib for Induction

SWOG S0120:  Protocol Summary | Consent Form

MGUS, asymptomatic Myeloma, or Solitary Plasmacytoma, not requiring tx; Observational Biologic Study (BM aspir & Perip Blood)

 TOP